

The Fifth RAS Initiative Symposium

 October 8 - 10, 2024


General Information

For conference-related questions
please contact

Conference Planning

 conferenceplanning@mail.nih.gov

Location

The Advanced Technology
Research Facility (ATRF) 8560 Progress Drive
Frederick, MD 21701 ADD TO CALENDAR[View](#) [Access control](#) [Edit](#) [Registrants](#) [Delete](#) [Clone](#)

Abstract Submission

This event is in person. There will be no virtual poster sessions. Please only submit an abstract if you plan to attend in person.

Preparing and Presenting your poster:

- Please make the dimensions of your poster no larger than 4' high X 6' long.
- Pushpins and Velcro will be available.
- Presenters are requested to stay near their posters during the poster session to field questions and discuss their findings.

Abstracts for consideration are welcome and due by **September 1, 2024 by 11:59pm**.

Guidelines for Abstract Submission:

Please follow the guidelines below for preparing your abstract. Abstracts that do not comply with the stated specifications may be returned for editing.

1. Please use Microsoft Word for PC or Mac to type your abstract. Be sure to save the abstract on your computer prior to uploading.
2. **File name should have the AUTHORS last name listed (example: 2022-Abstract-SMITH)**
3. Text should be single-spaced, 10-point Times New Roman font with 1-inch margins.
4. The body of the abstract must not exceed more than 400 words.
5. The first letter of each word in your TITLE should be capitalized.
6. List the authors' first and last names and affiliations in both uppercase and lowercase letters, directly below the title.
7. Underline the name of the presenting author
8. Identify the corresponding affiliation and location for each author.
9. Skip one line between the listing of authors and the text of your abstract.

Example:

Molecular Remissions of Hairy Cell Leukemia with Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox Correlate with Improved Complete Remission Duration in Phase 1 and 3 Testing.

Robert J. Kreitman¹, Daniel Gorelik¹, Maryalice Stetler-Stevenson², Constance Yuan², Mark Raffeld², Liqiang Xi², Mark Sokolsky¹, Hong Zhou¹, Nai Shun Yao³, Shannon Marshall³, Katherine Potocka¹, Erin Fykes¹, Evgeny Arons¹ and Ira Pastan¹.

1LMB
2LP, CCR, NCI

OMB No.: 0925-0740

Expiration Date: 09/30/2025

Public reporting burden for this collection of information is estimated to average 30 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA (0925-0740). Do not return the completed form to this address

Deadline is September 1, 2024.

Contact Information

FIRST NAME *

LAST NAME *

EMAIL *

CONFIRM EMAIL *

Submitting this form will NOT register you for the conference, you must use the Registration page to submit your information to secure your place as an attendee.

Abstract Information

ABSTRACT TITLE

AUTHOR(S)

AUTHOR AFFILIATION

ABSTRACT BODY

SUBMIT

RESET